Janssen Announces ERLEADA ® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news